A*STAR, NHCS, NUS, and Novo Nordisk partner to study the mechanisms underlying heart failure

By | May 13, 2022
The Agency for Science, Technology and Research’s Genome Institute of Singapore and Bioinformatics Institute, as well as the National Heart Centre Singapore, National University of Singapore, and pharmaceutical company Novo Nordisk have signed an agreement to study the mechanisms underlying cardiovascular disease progression-; especially the condition called heart failure with preserved ejection fraction (HFpEF).